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ABSTRACT
Background. The prognostic significance of primary
tumor location, especially the poor prognosis for melano-
mas in the scalp and neck region, is well established.
However, the prognosis for different sites of nodal ma-
crometastasis has never been studied. This study
investigated the prognostic value of the location of ma-
crometastasis in terms of recurrence and survival rates after
therapeutic lymph node dissection (TLND).
Methods. All consecutive FDG-PET-staged melanoma
patients with palpable and cytologically proven lymph node
metastases operated at our clinic between 2003 and 2011
were included. Disease-free survival and disease-specific
survival (DSS) were compared for nodal metastases in the
groin, axilla, and neck regions by multivariable analysis.
Results. A total of 149 patients underwent TLND; there
were 70 groin (47 %), 57 axillary (38 %), and 22 neck
(15 %) dissections. During a median follow-up of 18
(range 1–98) months, 102 patients (68 %) developed
recurrent disease. Distant recurrence was the first sign of
progressive disease in 78, 76, and 55 % of the groin, axilla,
and neck groups, respectively (p = 0.26). Low involved/
total lymph nodes (L/N) ratio (p \ 0.001) and absence of
extranodal growth pattern (p = 0.05) were independent
predictors of a longer disease-free survival. For DSS, neck
site of nodal metastasis (p = 0.02) and low L/N ratio
(p \ 0.001) were independent predictors of long survival.
The estimated 5-year DSS for the groin, axilla, and neck
sites was 28, 34, and 66 %, respectively.
Conclusions. There seems significantly longer DSS after
TLND for nodal macrometastases in the neck compared to
axillary and groin sites, although larger series should
confirm this finding.
The incidence of melanoma continues to increase in the
Western world. In the Netherlands, the incidence doubled
over the past two decades, to 26.3 per 100,000 in 2009 from
11.3 per 100,000 in 1989.1,2 Most patients present initially
with stage I or II melanoma.3 Unfortunately, despite defined
surgical treatment of the primary melanoma with excision
margins of 1 or 2 cm, approximately 16–28 % of patients
develop recurrent disease. These recurrences occur locally
or in transit in 20–28 %, distant in 15–50 %, but most
frequently in regional lymph nodes (26–60 %).4
When nodal recurrence is detectable clinically (stage
IIIB–C), patients may benefit from therapeutic lymph node
dissection (TLND) with or without adjuvant radiation
treatment in terms of regional tumor control and survival,
resulting in a 5-year survival rate of 29–52 %.3,5–9 Major
predictors of an unfavorable prognosis are greater Breslow
thickness, the presence of ulceration, and a high mitotic
rate. Clark level, location of the primary melanoma, age,
and sex are less important predictors.3,10 The prognostic
significance of primary melanoma characteristics cannot be
identified for patients with nodal metastasis undergoing
TLND.5 For this group of patients, a recent study showed
that a preoperatively elevated S-100B tumor marker had a
negative prognostic value.11
The prognostic significance of primary tumor location,
especially worse prognosis for melanomas in the scalp and
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neck region, is well established.12,13 However, the prog-
nostic value of the anatomic location of nodal recurrence in
stage IIIB–C melanoma has not previously been investi-
gated. Patients with nodal metastasis are at high risk for
distant metastasis. Therefore, patients with stage III mela-
noma and palpable lymph node metastases are staged by
whole body FDG-PET and spiral CT at our center since the
last decade, avoiding unnecessary surgery in the presence
of systemic disease in 15.5 % of these patients.14
The aim of the present study was to analyze the site of
recurrence, the disease-free survival (DFS), and the dis-
ease-specific survival (DSS) according to the anatomic
location of lymph node metastasis (groin, axilla, and neck)
in optimally staged patients with stage IIIB–C melanoma.
PATIENTS AND METHODS
All consecutive melanoma patients with palpable and
cytologically proven lymph node metastases diagnosed at
the Division of Surgical Oncology of the University
Medical Center Groningen (UMCG), the Netherlands,
between 2003 and 2011 underwent staging with whole-
body FDG-PET and spiral CT. All patients were informed
about their stage of disease, type of regional nodal dis-
section, and potential perioperative complications,
according to the UMCG standards. Those with distant
metastases or with more than one affected lymph node
basin were excluded from this study. A total of 149 stage
IIIB–C melanoma patients underwent a TLND. In this
group, only 7 patients had been staged previously with
sentinel lymph node biopsy, which was negative in 6 cases.
The single patient with a positive sentinel lymph node
biopsy refused a proposed completion lymph node dis-
section at the time and experienced disease recurrence later
in the affected regional lymph node basin.
All therapeutic dissections were performed by experi-
enced surgical oncologists. A level I–III axillary dissection
was performed with resection of the minor pectoral muscle.
Groin dissection comprised superficial (inguinal) and deep
(iliac and obturator) lymph node dissection with sartorius
muscle transposition.15 Neck dissection included radical
removal of lymph nodes in levels I–III, I–V, and II–V,
including the posterior compartment depending on indica-
tion. A subtotal dissection of the parotid gland was
performed depending on the localization of the lymph node
metastasis and the primary site.
Patients with positive lymph nodes larger than 3 cm, three
or more positive lymph nodes, and/or extranodal growth
pattern received adjuvant radiotherapy (45–60 Gy).16,17
All patients with recurrence after TLND were discussed
in a multidisciplinary melanoma conference and received
tailored treatment (surgery, radiotherapy, and/or systemic
treatment) according to the current standard or experi-
mental treatment protocols.
Characteristics of the patient (sex and age), primary
melanoma (Breslow thickness, Clark level, ulceration,
mitotic rate, and primary disease site), and lymph node
metastasis (interval to metastasis, extranodal growth pat-
tern, total number of nodes, number of involved nodes,
involved/total lymph nodes (L/N) ratio, and size of the
largest nodal metastasis) were recorded and analyzed for
differences between the groin, axillary, and neck groups.
Fisher’s exact test or the chi-square test for categorical
variables and the Kruskal–Wallis test for continuous vari-
ables were used to analyze the differences by using a
significance level of 5 %. DFS and DSS were calculated
from the date of the TLND. Univariate and multivariable
Cox proportional hazards analysis, as well as Kaplan-Meier
curves, were used to assess DFS and DSS for different
nodal metastasis locations, with an event defined as any
recurrence for DFS and death due to melanoma for DSS.
All factors significant at a 10 % significance level in uni-
variate analysis were included in a multivariable model
along with sex, age, Breslow thickness, and ulceration.
Quantitative characteristics were entered as continuous
variables in univariate and multivariable analysis on DFS
and DSS. Because of its prognostic significance, we used
the L/N ratio rather than the number of involved nodes for
multivariable analysis.18–20 A backward stepwise method
was then used to identify independent predictors for DFS
and DSS at the 5 % significance level.
RESULTS
A total of 149 patients underwent TLND. There were 70
groin dissections (47 %), 57 axillary dissections (38 %),
and 22 neck dissections (15 %). The median age was 58
(range 16–93) years, and 64 patients (43 %) were female.
Significant differences in characteristics between the
three lymph node basin groups were found for sex
(p = 0.001, with more males in the axilla and neck
groups), Clark level (p = 0.05, lower in neck group), total
number of collected nodes (p = 0.04, higher in neck
group), and size of largest lymph node metastasis at
pathologic examination (p \ 0.001, with smaller metasta-
ses in the neck group) (Table 1).
Site of Recurrence
One hundred two patients (68 %) developed recurrent
disease during follow-up. As shown in Table 2, a large
proportion of patients in the groin and axilla groups had
recurrent disease and presented with distant metastases as
the first sign of progressive disease (78 and 76 %). In the
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neck group, only 55 % of patients presented with a distant
metastasis as the first site of recurrence (p = 0.26).
Recurrence and Survival Rates
The follow-up for the entire group was 18 (range 1–98)
months with an estimated 5-year DFS of 27 % (95 % con-
fidence interval 19–34) and an estimated 5-year DSS of
37 % (95 % confidence interval 28–45). The estimated
5-year DFS for the groin, axilla, and neck groups was 12, 27,
and 49 %, respectively (Fig. 1a). Variables associated with
DFS in univariate analysis were presence of ulceration, the
location of nodal metastasis, extranodal growth pattern, L/N
ratio, and the size of the largest nodal metastasis. Neck
location of the metastasis showed a significantly longer DFS
in univariate analysis (Table 3). The multivariable model
showed a lower L/N ratio (p \ 0.001) and an absence of
extranodal growth pattern (p = 0.05) to be independent
predictors of longer DFS. The association of the location of
lymph node metastasis with DFS was not statistically sig-
nificant in the multivariable model (Table 4).
TABLE 1 Patient characteristics according to location of lymph node
metastasis
Characteristic No. of patients (%)
Groin Axilla Neck p
Sex
Female 41 (59) 19 (33) 4 (18) 0.001
Male 29 (41) 38 (67) 18 (82)
Age (year)
Median (range) 58 (29–87) 53 (25–93) 59 (16–82) 0.26
\50 17 (24) 24 (42) 7 (32)
50–64 32 (46) 19 (33) 5 (23)
65? 21 (30) 14 (25) 10 (45)
Breslow thickness (mm)
Median (range) 2.1 (0.1–16) 1.8 (0.4–8) 2.5 (0.5–14) 0.51
T1 (\1.00) 6 (9) 9 (16) 3 (13)
T2 (1.00–2.00) 24 (34) 18 (32) 5 (23)
T3 (2.00–4.00) 26 (37) 15 (26) 5 (23)
T4 ([4.00) 9 (13) 7 (12) 5 (23)
Unknown 5 (7) 8 (14) 4 (18)
Clark level
II/III 10 (17) 11 (26) 6 (32) 0.05
IV/V 45 (75) 26 (62) 7 (36)
Unknown 5 (8) 5 (12) 6 (32)
Unknown primary melanoma
No 67 (96) 52 (91) 19 (86) 0.27
Yes 3 (4) 5 (9) 3 (14)
Ulceration
Absent 42 (60) 30 (52) 14 (64) 0.16
Present 24 (34) 18 (32) 2 (9)
Unknown 4 (6) 9 (16) 6 (27)
Mitotic rate per mm2
Median (range) 5 (0–18) 4 (0–21) 4 (1–35) 0.89
\5 28 (40) 28 (49) 8 (36)
C5 29 (41) 19 (33) 6 (28)
Unknown 13 (19) 10 (18) 8 (36)
Interval between primary melanoma and nodal metastasis (year)a
Median (range) 2.1 (0–17) 1.9 (0–15) 1.2 (0–19) 0.65
B2 years 32 (48) 28 (54) 11 (58)
[2 years 35 (52) 24 (46) 8 (42)
Extranodal growth pattern
No 36 (51) 39 (68) 12 (54) 0.14
Yes 34 (49) 18 (32) 10 (46)
Total no. of nodes
Median (range) 15 (2–38) 16 (6–43) 24 (3–70) 0.04
No. of involved nodesb
Median (range) 3 (1–23) 2 (1–25) 2 (1–10) 0.27
N1 (1) 21 (30) 25 (44) 8 (36)
N2 (2–3) 22 (31) 15 (26) 7 (32)
N3 (4?) 27 (39) 7 (32) 7 (32)
Ratio of involved/total nodes (%)
Median (range) 15 (3–100) 15 (2–100) 10 (1–67) 0.12
B10 24 (34) 24 (42) 11 (50)
TABLE 2 Site of first recurrence after therapeutic lymph node dis-
section according to location of lymph node metastasis
Site of recurrencea Local Locoregional Distant p
Groin 2 (4) 10 (18) 42 (78) 0.26
Axilla 4 (11) 5 (13) 28 (76)
Neck 1 (9) 4 (36) 6 (55)
a Patients presenting with both local or locoregional and distant
recurrences were classified as distant
TABLE 1 continued
Characteristic No. of patients (%)
Groin Axilla Neck p
10–25 19 (27) 18 (32) 8 (36)
[25 27 (39) 15 (26) 3 (7)
Size of nodal metastasis (cm)
Median (range) 2.8 (0.1–7.0) 5.0 (1.5–9.0) 2.2 (0.3–6.0) \0.001
\3.0 35 (50) 14 (25) 16 (73)
C3.0 33 (47) 41 (72) 5 (23)
Unknown 2 (3) 2 (3) 1 (4)
AJCC stageb
IIIB 26 (37) 26 (46) 14 (64) 0.09
IIIC 44 (63) 31 (54) 8 (36)
Duration of follow-up (months)
Median (range) 19 (1–93) 16 (1–98) 43 (3–94) 0.05
p-values below 0.05 in bold
a Unknown primary melanoma not included in calculation of interval
b According to the 7th melanoma classification of the American Joint
Committee on Cancer
Prognosis for Different Sites of Nodal Metastases 3915
The estimated 5-year DSS was 28, 34, and 66 % for
groin, axilla, and neck, respectively (Fig. 1b). Variables
associated with DSS in univariate analysis were the loca-
tion of nodal metastasis, extranodal growth pattern, L/N
ratio, and the size of the largest nodal metastasis (Table 3).
The multivariable model for DSS revealed neck site of
metastasis (p = 0.02) (Table 4) and a lower L/N ratio
(p \ 0.001) to be significantly associated with better
survival.
DISCUSSION
Analysis of 149 melanoma patients undergoing curative
TLND showed the 5-year DSS to be 37 % for the entire
group, which is similar to percentages reported in the lit-
erature.5,21 Univariate and multivariable analysis revealed
differences in prognosis for metastasis in the groin, axilla,
or neck. Specifically, nodal metastasis located in the neck
was associated with significantly better DSS. No statisti-
cally significant difference was found for frequency of
distant metastases as the first site of recurrence: groin
group 78 %, axilla group 76 %, and neck group 55 %
(p = 0.26).
In the present study, significant prognostic factors for
survival in univariate analysis were site of nodal metastasis,
extranodal growth pattern, L/N ratio, and size of the largest
nodal metastasis. Besides neck site of nodal metastasis, low
L/N ratio was found to be an independent predictor for
better DSS, a finding that is in agreement with the recent
literature.18–20 Primary melanoma characteristics were not
associated with survival, which is consistent with the study
of 441 stage IIIB–C melanoma patients by Balch et al.3,5
Finding longer survival for neck site metastasis seems
contrary to the observation that head and neck melanomas
have a worse prognosis than melanomas at other sites.12,13
However, the literature currently lacks specific studies
regarding the prognostic value of the site of nodal metas-
tasis. Moreover, a recent study on the outcome of TLND in
stage III melanoma patients with an unknown primary
melanoma did notice a survival benefit for patients with a
neck metastasis compared to groin or axillary metastasis.21
The better prognosis for patients with neck metastasis
could be explained by earlier detection of nodal metastasis,
resulting in a smaller tumor burden at time of the TLND,
and of recurrent locoregional disease in the neck, because
of the more superficial and notable position of nodes
compared to those in the groin or axilla. In support of this,
we found that the lymph node metastases in the neck group
were significantly smaller than in the groin and axilla
groups. In addition, there was a tendency for patients in the
neck group to present more frequently with local or loco-
regional recurrence as the first sign of progressive disease,
rather than distant disease, compared to the groin and axilla
groups. However, with the current study size, this tendency
did not reach statistical significance.
To evaluate the outcomes of nodal metastasis at differ-
ent locations without the detection benefit of superficial




















































































































FIG. 1 Kaplan–Meier curves for disease-free survival (a) and disease-specific survival (b) according to location of lymph node metastasis
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117 patients who underwent completion lymph node dis-
section shortly after positive sentinel lymph node biopsy in
a study by de Vries et al.22 This subanalysis showed a
5-year DSS of 63, 68, and 75 % for the groin, axilla, and
neck groups, respectively. Although the difference in sur-
vival was not statistically significant, the more favorable
number for metastasis at the neck site is notable. Therefore,
we concluded that the detection benefit alone, even though
it proved to be important, could not fully explain the sur-
vival difference. Another hypothesis that could explain our
findings is the effect of a more extensive lymphatic system
in the neck region, which could keep metastases from
hematogenous spread. In this case, we would expect dif-
ferences in the percentage of patients whose disease was
upstaged with PET or CT after presenting with palpable
lymph node metastases at the different locations. However,
in a previous study, we found no differences in the per-
centage of upstaging between the groups of patients with
groin, axilla, or neck metastases (18.3 % groin, 31.3 %
axilla, and 23.3 % neck; p = 0.12).14 The exact mecha-
nisms underlying better survival thus remain unknown.
However, possibilities include differences in the behavior
of the primary melanoma, a lower detection threshold,
immunological advantages of the nodal basin in the neck,
and dissection effects.
The findings of this study are limited by the rather small
group of patients who underwent TLND of the neck
(n = 22). Therefore, definitive establishment of the more
favorable prognosis for macrometastasis when located in
the neck needs confirmation by larger series.
TABLE 3 Univariate Cox regression analysis of prognostic factors
for DFS and DSS
Characteristic DFS DSS
HR 95 % CI p HR 95 % CI p
Sex
Female 1 1
Male 1.07 0.72–1.59 0.73 1.28 0.83–1.98 0.26
Age (years)
Continuous 0.99 0.98–1.00 0.15 1.00 0.98–1.01 0.70
\50 1 1
50–64 0.93 0.58–1.49 1.07 0.64–1.80
C65 0.88 0.54–1.43 1.15 0.67–1.99
Breslow thickness (mm)
Continuous 0.98 0.89–1.07 0.60 0.98 0.89–1.09 0.74
T1 (\1.00) 1 1
T2
(1.00–2.00)
0.79 0.40–1.56 1.10 0.50–2.42
T3
(2.00–4.00)
1.09 0.56–2.09 1.17 0.53–2.57
T4 ([4.00) 0.73 0.33–1.61 0.86 0.35–2.15
Clark level
II 1 1
III 1.77 0.41–7.70 0.46 3.71 0.48–28.5 0.21
IV 2.55 0.63–10.44 0.20 4.86 0.67–35.2 0.12
V 2.29 0.46–11.34 0.32 3.60 0.40–32.4 0.25
Unknown primary melanoma
No 1 1
Yes 1,66 0.72–3.83 0.23 1.29 0.56–2.97 0.55
Location of primary melanoma
Arm 1 1
Leg 1.64 0.77–3.49 0.20 1.55 0.68–3.53 0.29
Trunk 1.42 0.65–3.08 0.37 1.59 0.69–3.67 0.28
Head/neck 0.54 0.19–1.57 0.26 0.56 0.17–1.73 0.31
Ulceration
Present 1 1
Absent 0.64 0.42–0.99 0.05 0.72 0.44–1.16 0.18
Mitotic rate per mm2
Continuous 1.00 0.97–1.04 0.86 1.00 0.96–1.05 0.84
\5 1 1
C5 1.19 0.76–1.87 1.13 0.69–1.86
Interval between primary melanoma and nodal metastasis (years)
Continuous 0.95 0.90–1.01 0.11 0.90 0.88–1.01 0.09
Location metastasis
Groin 1 1
Axilla 0.84 0.55–1.28 0.42 0.99 0.63–1.56 0.97
Neck 0.42 0.22–0.81 0.009 0.34 0.15–0.77 0.009
Extranodal growth pattern
No 1 1
Yes 1.96 1.33–2.90 0.001 1.86 1.21–2.85 0.004
No. of involved nodes
Continuous 1.06 1.03–1.10 0.001 1.07 1.03–1.12 0.001
TABLE 3 continued
Characteristic DFS DSS
HR 95 % CI p HR 95 % CI p
N1 (1) 1 1
N2 (2–3) 1.32 0.76–2.31 0.99 1.56–1.74
N3 (4?) 2.42 1.42–4.11 2.33 1.40–3.88
Ratio of involved/total nodes (%)
Continuous 1.02 1.01–1.02 \0.001 1.01 1.01–1.02 \0.001
B10 1 1
10–25 1.27 0.73–2.22 1.25 0.71–2.18
[25 2.30 1.37–3.88 2.69 1.60–4.52
Size the lymph node metastasis (cm)
Continuous 1.14 1.02–1.26 0.02 1.17 1.05–1.31 0.004
\3.0 1 1
C3.0 1.40 0.94–2.09 1.71 1.09–2.68
p-values below 0.05 in bold
DFS disease-free survival, DSS disease-specific survival, HR hazard
ratio, CI confidence interval
All variables with p \ 0.10 were included in multivariable model
along with sex, age, Breslow thickness, and ulceration
Prognosis for Different Sites of Nodal Metastases 3917
In conclusion, this study showed better prognosis after
TLND for stage IIIB–C melanoma when the lymph node
metastasis is located in the neck compared to axillary and
groin sites.
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